- Home
- REFI vs XOMA Comparison
REFI vs XOMA Comparison
Compare REFI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | XOMA |
|---|---|---|
| Founded | 2021 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.9M | 471.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | XOMA |
|---|---|---|
| Price | $12.25 | $41.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $52.50 |
| AVG Volume (30 Days) | 121.4K | ★ 388.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $17.47 | $24.59 |
| Revenue Next Year | $0.06 | N/A |
| P/E Ratio | ★ $7.29 | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.74 | $22.29 |
| 52 Week High | $15.20 | $42.81 |
Technical Indicators
Market Signals| Indicator | REFI | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 71.18 |
| Support Level | $12.23 | $24.38 |
| Resistance Level | $12.47 | $42.81 |
| Average True Range (ATR) | 0.24 | 1.22 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 82.81 | 79.69 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.